Dementia update 2005

Keyphrases

• Dementia 100%
• Frontotemporal Lobar Degeneration 100%
• Risk Reduction 66%
• Clinical Methods 66%
• Acetylcholinesterase Inhibitors (AChEI) 66%
• Dementing Disorders 66%
• Preclinical Stage 66%
• Diagnostic Tool 33%
• Risk Factors 33%
• Older Adults 33%
• Cost-effectiveness 33%
• United States 33%
• High Dose 33%
• Insults 33%
• Monoclonal Antibody 33%
• Cognitive Impairment 33%
• Molecular Imaging 33%
• PET Study 33%
• Family History 33%
• Objective Assessment 33%
• Neuropathology 33%
• Statins 33%
• Estrogen Replacement Therapy 33%
• Physical Activity 33%
• Creutzfeldt-Jakob Disease 33%
• Non-steroidal Anti-inflammatory Drugs (NSAIDs) 33%
• Decreased Risk 33%
• Vitamin E 33%
• Vitamin C 33%
• Prodromal 33%
• Clinical Diagnosis 33%
• Motor Neuron Disease 33%
• Anti-A 33%
• Diagnostic Assessment 33%
• Surrogate Marker 33%
• Reimbursement 33%
• Dementia Diagnosis 33%
• Cognitive Activity 33%
• Social Activity 33%
• APOE Genotype 33%
• Antecedent Biomarkers 33%
• Dementia with Lewy Bodies 33%
• Rate of Cognitive Decline 33%
• Memantine 33%
• Mixed Dementia 33%
• Inhibitor Therapy 33%
• Vascular Dementia 33%
• Atypical Antipsychotics 33%
• Vascular Pathology 33%
• Neuroimaging Findings 33%
• Conclusive Evidence 33%
• Inhibitor Drug 33%
• Multiple Candidates 33%
• Modulating Factors 33%
• Symptomatic Therapy 33%
• Dementia Research 33%
• Sporadic AD 33%
• Informant Interviews 33%
• Passive Administration 33%
• AD Process 33%
• Optimal Period 33%
• MCI Criteria 33%
• Prodromal AD 33%
• Neuroimaging Measures 33%
• Prognostic Tool 33%
• Immunotherapeutic Strategies 33%
• Symptomatic Stage 33%
• Amyloid Tracers 33%
• Dementia Severity 33%
• Interview Assessment 33%
• Antioxidant Vitamin E 33%
• Cardiovascular Factors 33%

Neuroscience

• Acetylcholinesterase Inhibitor 100%
• Clinical Method 100%
• Vitamin E 100%
• Biological Marker 100%
• Cognitive Disorders 50%
• Monoclonal Antibody 50%
• Molecular Imaging 50%
• Positron Emission Tomography 50%
• Creutzfeldt Jakob Disease 50%
• Motor Neuron Disease 50%
• Blood Group A Antibody 50%
• Cardiovascular System 50%
• Dementia with Lewy Bodies 50%
• Antioxidant 50%
• Non-Steroidal Anti-Inflammatory Drug 50%
• Memantine 50%
• Atypical Antipsychotic 50%
• Statin 50%
• Amyloid Protein 50%
• Vascular Dementia 50%
• Estrogen Replacement Therapy 50%
• Risk Factor 50%
• Older Adults 50%
• Cognitive Decline 50%

Medicine and Dentistry

• Frontotemporal Lobar Degeneration 100%
• Biological Marker 66%
• Alpha Tocopherol 66%
• Clinical Method 66%
• Acetylcholinesterase Inhibitor 66%
• Diseases 66%
• Health Care Cost 33%
• Molecular Imaging 33%
• Drug Megadose 33%
• Estrogen Therapy 33%
• Supplementation 33%
• Monoclonal Antibody 33%
• Cognitive Defect 33%
• Nonsteroid Antiinflammatory Agent 33%
• Family History 33%
• Statin 33%
• Disease Marker 33%
• Antioxidant 33%
• Amyloid Protein 33%
• Atypical Antipsychotics 33%
• Blood Group A Antibody 33%
• Diffuse Lewy Body Disease 33%
• Vascular Dementia 33%
• Creutzfeldt-Jakob Disease 33%
• Memantine 33%
• Motor Neuron Disease 33%
• Cardiovascular System 33%
• Polyethylene Terephthalate 33%
• Cognitive Decline 33%
• Vitamin C 33%